Cyclerion Therapeutics Inc. Common Stock (CYCN)
Stock · NASDAQ · Health Care
$3.36as of 10/14/2026
Price chart
Active signals
CYCN Signal Track Record
How signals performed across all stocks →What CYCN's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakout | 22 | -19.2% | 36% | September 3, 2026 |
| Volume SpikeActive now | 21 | -7.6% | 43% | August 27, 2026 |
| Bollinger Band Breakdown | 19 | -2.5% | 37% | December 29, 2025 |
| 200-Day Moving Average TouchActive now | 15 | -7.0% | 40% | June 30, 2025 |
| Any 20-session window (baseline) | -1.5% | 46% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About CYCN
Cyclerion Therapeutics, Inc., a biopharmaceutical company, engages in the development of treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. The company is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Pralicig…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 1
- Website
- www.cyclerion.com/
Fundamentals
- 1-day range
- Market cap
- $16.67M
- P/E (trailing)
- —
- P/E (forward)
- -2.56
- EPS (trailing)
- $-1.68
- Dividend yield
- —
- Beta
- 1.83
- Avg. volume
- 7.9K
How Cyclerion Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 31, 2026 · via SEC EDGAR / Finnhub
Forecasts
1 analyst ratings
Cyclerion Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- CYCNCyclerion Therapeutics Inc. Common Stock$3.36▼ 0.15%Market cap $16.67MP/E —$7.19$59.36
- SKYESkye Bioscience Inc. Common Stock$1.55▼ 2.52%Market cap $16.58MP/E —$1.5$13.28
- MDCXMedicus Pharma Ltd. Common Stock$3.25▼ 5.25%Market cap $16.97MP/E —$0.144$2.78
- BFRIBiofrontera Inc. Common Stock$0.822▼ 2.95%Market cap $16.00MP/E —$0.555$1.66
- LPCNLipocine Inc. Common Stock$1.56▼ 7.14%Market cap $17.56MP/E —$1.59$12.37
- CTXRCitius Pharmaceuticals Inc. Common Stock$0.46▲ 0.00%Market cap $17.62MP/E —$0.46$2.19
- NCELNewcelX Ltd. Ordinary Shares$2.5▼ 12.28%Market cap $17.98MP/E —$1.83$18.4
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CYCN Cyclerion Therapeutics Inc. Common Stock | $16.67M | — | $3.36 | ▼ 0.15% | $7.19$59.36 |
| SKYE Skye Bioscience Inc. Common Stock | $16.58M | — | $1.55 | ▼ 2.52% | $1.5$13.28 |
| MDCX Medicus Pharma Ltd. Common Stock | $16.97M | — | $3.25 | ▼ 5.25% | $0.144$2.78 |
| BFRI Biofrontera Inc. Common Stock | $16.00M | — | $0.822 | ▼ 2.95% | $0.555$1.66 |
| LPCN Lipocine Inc. Common Stock | $17.56M | — | $1.56 | ▼ 7.14% | $1.59$12.37 |
| CTXR Citius Pharmaceuticals Inc. Common Stock | $17.62M | — | $0.46 | ▲ 0.00% | $0.46$2.19 |
| NCEL NewcelX Ltd. Ordinary Shares | $17.98M | — | $2.5 | ▼ 12.28% | $1.83$18.4 |
P/E shows — for peers not currently carrying a live signal of their own.
Insider Activity
Insider Actions →- Peter M. Hecht · July 16, 2026 · Conversion351.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 154.6K
- Total value held
- $237.7K
- Institutional holders
- 16
- Unknown84.5K
- Unknown18.3K
- Unknown16.8K
- Unknown16.1K
- Unknown10.0K
- Unknown4.7K
- Unknown3.4K
- Unknown192
- Unknown130
- Unknown100
See the full, filterable feed with live charts on the MarketWall dashboard.